Carter et al. emphasized the importance of selected therapy trough molecular analysis of cancer cells using IHC, with the intention to increase patients’ benefits, and ERCC1 was evaluated as a predictor of better outcome in lung adenocarcinoma patients [21]. The gene discussed is ERCC1; the disease is lung adenocarcinoma.